179 related articles for article (PubMed ID: 31392115)
1. Evaluation of the serum metabolome of patients with alkaptonuria before and after two years of treatment with nitisinone using LC-QTOF-MS.
Davison AS; Norman BP; Ross GA; Hughes AT; Khedr M; Milan AM; Gallagher JA; Ranganath LR
JIMD Rep; 2019 Jul; 48(1):67-74. PubMed ID: 31392115
[TBL] [Abstract][Full Text] [Related]
2. Impact of Nitisinone on the Cerebrospinal Fluid Metabolome of a Murine Model of Alkaptonuria.
Davison AS; Norman BP; Sutherland H; Milan AM; Gallagher JA; Jarvis JC; Ranganath LR
Metabolites; 2022 May; 12(6):. PubMed ID: 35736410
[TBL] [Abstract][Full Text] [Related]
3. A Comprehensive LC-QTOF-MS Metabolic Phenotyping Strategy: Application to Alkaptonuria.
Norman BP; Davison AS; Ross GA; Milan AM; Hughes AT; Sutherland H; Jarvis JC; Roberts NB; Gallagher JA; Ranganath LR
Clin Chem; 2019 Apr; 65(4):530-539. PubMed ID: 30782595
[TBL] [Abstract][Full Text] [Related]
4. Metabolomic studies in the inborn error of metabolism alkaptonuria reveal new biotransformations in tyrosine metabolism.
Norman BP; Davison AS; Hughes JH; Sutherland H; Wilson PJ; Berry NG; Hughes AT; Milan AM; Jarvis JC; Roberts NB; Ranganath LR; Bou-Gharios G; Gallagher JA
Genes Dis; 2022 Jul; 9(4):1129-1142. PubMed ID: 35685462
[TBL] [Abstract][Full Text] [Related]
5. Assessing the effect of nitisinone induced hypertyrosinaemia on monoamine neurotransmitters in brain tissue from a murine model of alkaptonuria using mass spectrometry imaging.
Davison AS; Strittmatter N; Sutherland H; Hughes AT; Hughes J; Bou-Gharios G; Milan AM; Goodwin RJA; Ranganath LR; Gallagher JA
Metabolomics; 2019 Apr; 15(5):68. PubMed ID: 31037385
[TBL] [Abstract][Full Text] [Related]
6. Quantification of the flux of tyrosine pathway metabolites during nitisinone treatment of Alkaptonuria.
Milan AM; Hughes AT; Davison AS; Khedr M; Rovensky J; Psarelli EE; Cox TF; Rhodes NP; Gallagher JA; Ranganath LR
Sci Rep; 2019 Jul; 9(1):10024. PubMed ID: 31296884
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Biotransformation Analysis of Phenylalanine-Tyrosine Metabolism Reveals Alternative Routes of Metabolite Clearance in Nitisinone-Treated Alkaptonuria.
Norman BP; Davison AS; Hickton B; Ross GA; Milan AM; Hughes AT; Wilson PJM; Sutherland H; Hughes JH; Roberts NB; Bou-Gharios G; Gallagher JA; Ranganath LR
Metabolites; 2022 Sep; 12(10):. PubMed ID: 36295829
[TBL] [Abstract][Full Text] [Related]
8. Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuria.
Hughes JH; Wilson PJM; Sutherland H; Judd S; Hughes AT; Milan AM; Jarvis JC; Bou-Gharios G; Ranganath LR; Gallagher JA
J Inherit Metab Dis; 2020 Mar; 43(2):259-268. PubMed ID: 31503358
[TBL] [Abstract][Full Text] [Related]
9. Nitisinone arrests ochronosis and decreases rate of progression of Alkaptonuria: Evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria Centre.
Ranganath LR; Khedr M; Milan AM; Davison AS; Hughes AT; Usher JL; Taylor S; Loftus N; Daroszewska A; West E; Jones A; Briggs M; Fisher M; McCormick M; Judd S; Vinjamuri S; Griffin R; Psarelli EE; Cox TF; Sireau N; Dillon JP; Devine JM; Hughes G; Harrold J; Barton GJ; Jarvis JC; Gallagher JA
Mol Genet Metab; 2018 Sep; 125(1-2):127-134. PubMed ID: 30055994
[TBL] [Abstract][Full Text] [Related]
10. Clinical and biochemical assessment of depressive symptoms in patients with Alkaptonuria before and after two years of treatment with nitisinone.
Davison AS; Harrold JA; Hughes G; Norman BP; Devine J; Usher J; Hughes AT; Khedr M; Gallagher JA; Milan AM; J C G H; Ranganath LR
Mol Genet Metab; 2018 Sep; 125(1-2):135-143. PubMed ID: 30049652
[TBL] [Abstract][Full Text] [Related]
11. Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment.
Ranganath LR; Milan AM; Hughes AT; Dutton JJ; Fitzgerald R; Briggs MC; Bygott H; Psarelli EE; Cox TF; Gallagher JA; Jarvis JC; van Kan C; Hall AK; Laan D; Olsson B; Szamosi J; Rudebeck M; Kullenberg T; Cronlund A; Svensson L; Junestrand C; Ayoob H; Timmis OG; Sireau N; Le Quan Sang KH; Genovese F; Braconi D; Santucci A; Nemethova M; Zatkova A; McCaffrey J; Christensen P; Ross G; Imrich R; Rovensky J
Ann Rheum Dis; 2016 Feb; 75(2):362-7. PubMed ID: 25475116
[TBL] [Abstract][Full Text] [Related]
12. Revisiting Quantification of Phenylalanine/Tyrosine Flux in the Ochronotic Pathway during Long-Term Nitisinone Treatment of Alkaptonuria.
Ranganath LR; Hughes AT; Davison AS; Khedr M; Imrich R; Rudebeck M; Olsson B; Norman BP; Bou-Gharios G; Gallagher JA; Milan AM
Metabolites; 2022 Sep; 12(10):. PubMed ID: 36295821
[TBL] [Abstract][Full Text] [Related]
13. Serum markers in alkaptonuria: simultaneous analysis of homogentisic acid, tyrosine and nitisinone by liquid chromatography tandem mass spectrometry.
Hughes AT; Milan AM; Davison AS; Christensen P; Ross G; Gallagher JA; Dutton JJ; Ranganath LR
Ann Clin Biochem; 2015 Sep; 52(Pt 5):597-605. PubMed ID: 25628464
[TBL] [Abstract][Full Text] [Related]
14. Nutritional interventions for patients with alkaptonuria: A minireview.
Imrich R; Zatkova A; Lukacova O; Sedlakova J; Zanova E; Vlcek M; Penesova A; Radikova Z; Havranova A; Ranganath L
Endocr Regul; 2023 Jan; 57(1):61-67. PubMed ID: 36966367
[TBL] [Abstract][Full Text] [Related]
15. Interference of hydroxyphenylpyruvic acid, hydroxyphenyllactic acid and tyrosine on routine serum and urine clinical chemistry assays; implications for biochemical monitoring of patients with alkaptonuria treated with nitisinone.
Curtis SL; Norman BP; Milan AM; Gallagher JA; Olsson B; Ranganath LR; Roberts NB
Clin Biochem; 2019 Sep; 71():24-30. PubMed ID: 31228435
[TBL] [Abstract][Full Text] [Related]
16. Relationship Between Serum Concentrations of Nitisinone and Its Effect on Homogentisic Acid and Tyrosine in Patients with Alkaptonuria.
Olsson B; Cox TF; Psarelli EE; Szamosi J; Hughes AT; Milan AM; Hall AK; Rovensky J; Ranganath LR
JIMD Rep; 2015; 24():21-7. PubMed ID: 25772318
[TBL] [Abstract][Full Text] [Related]
17. Serum Amino Acid Profiling in Patients with Alkaptonuria Before and After Treatment with Nitisinone.
Davison AS; Norman BP; Smith EA; Devine J; Usher J; Hughes AT; Khedr M; Milan AM; Gallagher JA; Ranganath LR
JIMD Rep; 2018; 41():109-117. PubMed ID: 29754208
[TBL] [Abstract][Full Text] [Related]
18. Association of alkaptonuria and low dose nitisinone therapy with cataract formation in a large cohort of patients.
Ahmad MSZ; Ahmed M; Khedr M; Borgia A; Madden A; Ranganath LR; Kaye S
JIMD Rep; 2022 Jul; 63(4):351-360. PubMed ID: 35822094
[TBL] [Abstract][Full Text] [Related]
19. Comparing nitisinone 2 mg and 10 mg in the treatment of alkaptonuria-An approach using statistical modelling.
Ranganath LR; Milan AM; Hughes AT; Khedr M; Norman BP; Alsbou M; Imrich R; Gornall M; Sireau N; Gallagher JA; Jackson R
JIMD Rep; 2022 Jan; 63(1):80-92. PubMed ID: 35028273
[TBL] [Abstract][Full Text] [Related]
20. Hepatobiliary circulation and dominant urinary excretion of homogentisic acid in a mouse model of alkaptonuria.
Norman BP; Sutherland H; Wilson PJM; Rutland DA; Milan AM; Hughes AT; Davison AS; Khedr M; Jarvis JC; Gallagher JA; Bou-Gharios G; Ranganath LR
J Inherit Metab Dis; 2024 Mar; ():. PubMed ID: 38487984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]